-
Product Insights
Ewing Sarcoma: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Ewing Sarcoma - Global Clinical Trials Review, 2026" provides an overview of Ewing Sarcoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Ewing Sarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Chondrosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Chondrosarcoma therapeutics. • In 2024, more than 13,000 diagnosed incident cases of CS are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for CS. • Currently, no approved disease-modifying therapy is available globally in the market space for CS. • R&D activities for CS are moderate with 29 molecules in the pipeline, out of which Phase III holds only one drug, whereas Phase II...
-
Product Insights
Ewing Sarcoma - Drugs In Development, 2024
Empower your strategies with our Ewing Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Ewing sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing sarcoma can occur at any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site...
-
Product Insights
Chondrosarcoma - Drugs In Development, 2024
Empower your strategies with our Chondrosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, and changes in urination....
-
Sector Analysis
Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Ewing Sarcoma Marketed and Pipeline Drugs Report Overview Ewing sarcoma (ES) is an aggressive tumor of adolescents and young adults that constitutes 10% to 15% of all bone sarcomas. The disease is named after James Ewing, who first described it in 1921. These sarcomas originate from unique mesenchymal progenitor cells due to their similar histologic and immunohistochemical characteristics. The most common anatomical sites include the pelvis, axial skeleton, and femur; however, it may occur in almost any bone or soft...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.